Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers.

Pilie P, Gay CM, Byers LA, O'Connor MJ, Yap TA.

Clin Cancer Res. 2019 Feb 13. pii: clincanres.0968.2018. doi: 10.1158/1078-0432.CCR-18-0968. [Epub ahead of print]

PMID:
30760478
2.

The association of mycophenolate mofetil and human herpes virus infection.

Yun JSW, Yap T, Martyres R, Kern JS, Varigos G, Scardamaglia L.

J Dermatolog Treat. 2019 Jan 24:1-32. doi: 10.1080/09546634.2019.1572864. [Epub ahead of print]

PMID:
30676825
3.

Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.

Shah TT, Peters M, Eldred-Evans D, Miah S, Yap T, Faure-Walker NA, Hosking-Jervis F, Thomas B, Dudderidge T, Hindley RG, McCracken S, Greene D, Nigam R, Valerio M, Minhas S, Winkler M, Arya M, Ahmed HU.

Eur Urol. 2019 Jan 8. pii: S0302-2838(18)31036-4. doi: 10.1016/j.eururo.2018.12.030. [Epub ahead of print]

PMID:
30638633
4.

Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL.

J Natl Cancer Inst. 2019 Feb 1;111(2):118-128. doi: 10.1093/jnci/djy196.

5.

The impact of human herpesvirus detection in pemphigus vulgaris.

Yang GQQ, Yap T, Martyres R, Varigos GA, Scardamaglia L.

Australas J Dermatol. 2018 Dec 9. doi: 10.1111/ajd.12977. [Epub ahead of print] No abstract available.

PMID:
30537024
6.

Development of PARP and Immune-Checkpoint Inhibitor Combinations.

Stewart RA, Pilié PG, Yap TA.

Cancer Res. 2018 Dec 15;78(24):6717-6725. doi: 10.1158/0008-5472.CAN-18-2652. Epub 2018 Nov 29. Review.

PMID:
30498083
7.

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.

Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G.

Cancer Res. 2019 Jan 15;79(2):311-319. doi: 10.1158/0008-5472.CAN-18-1003. Epub 2018 Nov 27.

PMID:
30482774
8.

Moving Precision Oncology Forward Amid Myths and Misconceptions.

Janku F, Hess KR, Yap TA.

JAMA Oncol. 2018 Dec 1;4(12):1788-1789. doi: 10.1001/jamaoncol.2018.5064. No abstract available.

PMID:
30419079
9.

A novel noninvasive appendicitis score with a urine biomarker.

Yap TL, Fan JD, Chen Y, Ho MF, Choo CS, Allen J, Low Y, Jacobsen AS, Nah SA.

J Pediatr Surg. 2019 Jan;54(1):91-96. doi: 10.1016/j.jpedsurg.2018.10.025. Epub 2018 Oct 5.

10.

Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.

Al-Saffar NMS, Troy H, Wong Te Fong AC, Paravati R, Jackson LE, Gowan S, Boult JKR, Robinson SP, Eccles SA, Yap TA, Leach MO, Chung YL.

Br J Cancer. 2018 Oct;119(9):1118-1128. doi: 10.1038/s41416-018-0242-3. Epub 2018 Oct 31.

PMID:
30377337
11.

State-of-the-art strategies for targeting the DNA damage response in cancer.

Pilié PG, Tang C, Mills GB, Yap TA.

Nat Rev Clin Oncol. 2019 Feb;16(2):81-104. doi: 10.1038/s41571-018-0114-z. Review.

PMID:
30356138
12.

Changing Team Member Perceptions by Implementing TeamSTEPPS in an Emergency Department.

Obenrader C, Broome ME, Yap TL, Jamison F.

J Emerg Nurs. 2019 Jan;45(1):31-37. doi: 10.1016/j.jen.2018.08.006. Epub 2018 Oct 12.

PMID:
30322675
13.

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.

O'Carrigan B, Lim JSJ, Jalil A, Harris SJ, Papadatos-Pastos D, Banerji U, Lopez J, de Bono JS, Yap TA.

Br J Cancer. 2018 Oct;119(8):922-927. doi: 10.1038/s41416-018-0290-8. Epub 2018 Oct 15.

PMID:
30318518
14.

Nonclonal Chromosomal Aberrations in Childhood Leukemia Survivors.

Chin TF, Ibrahim K, Thirunavakarasu T, Azanan MS, Oh L, Lum SH, Yap TY, Ariffin H.

Fetal Pediatr Pathol. 2018 Aug;37(4):243-253. doi: 10.1080/15513815.2018.1492054. Epub 2018 Oct 1.

PMID:
30273079
15.

Testosterone Therapy for High-risk Prostate Cancer Survivors: A Systematic Review and Meta-analysis.

Teeling F, Raison N, Shabbir M, Yap T, Dasgupta P, Ahmed K.

Urology. 2018 Sep 21. pii: S0090-4295(18)30993-2. doi: 10.1016/j.urology.2018.07.064. [Epub ahead of print] Review.

PMID:
30244116
16.

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.

O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J.

Cancer Chemother Pharmacol. 2018 Nov;82(5):757-766. doi: 10.1007/s00280-018-3661-1. Epub 2018 Aug 7.

17.

Targeting gamma secretase: has progress moved up a Notch?

Ileana Dumbrava EE, Mills GB, Yap TA.

Ann Oncol. 2018 Sep 1;29(9):1889-1891. doi: 10.1093/annonc/mdy307. No abstract available.

PMID:
30084907
18.

Fertility managment in testicular cancer: the need to establish a standardized and evidence-based patient-centric pathway.

Moody JA, Ahmed K, Yap T, Minhas S, Shabbir M.

BJU Int. 2019 Jan;123(1):160-172. doi: 10.1111/bju.14455. Epub 2018 Jul 27. Review.

PMID:
29920910
19.

Real-Time Imaging of Retinal Ganglion Cell Apoptosis.

Yap TE, Donna P, Almonte MT, Cordeiro MF.

Cells. 2018 Jun 15;7(6). pii: E60. doi: 10.3390/cells7060060. Review.

20.

Combination drug development in BRAF mutant colorectal cancer.

Lam M, Pant S, Yap TA.

Oncoscience. 2018 Apr 29;5(3-4):51-53. doi: 10.18632/oncoscience.399. eCollection 2018 Mar. No abstract available.

21.

Challenges with biomarkers in cancer drug discovery and development.

Ileana Dumbrava E, Meric-Bernstam F, Yap TA.

Expert Opin Drug Discov. 2018 Aug;13(8):685-690. doi: 10.1080/17460441.2018.1479740. Epub 2018 May 24. No abstract available.

PMID:
29792354
22.

Predicting the Presence of Oral Squamous Cell Carcinoma Using Commonly Dysregulated MicroRNA in Oral Swirls.

Yap T, Koo K, Cheng L, Vella LJ, Hill AF, Reynolds E, Nastri A, Cirillo N, Seers C, McCullough M.

Cancer Prev Res (Phila). 2018 Aug;11(8):491-502. doi: 10.1158/1940-6207.CAPR-17-0409. Epub 2018 May 15.

PMID:
29764807
23.

Reporting on longitudinal live birth rates and cumulative delivery rates are more realistic outcome measures than sperm retrieval rates in couples undergoing mTESE-ICSI.

Almekaty K, Abomelha S, Thum Y, Nicopoullos J, Bracewell-Milnes T, Yap T, Minhas S.

Hum Fertil (Camb). 2018 May 10:1-6. doi: 10.1080/14647273.2018.1472396. [Epub ahead of print]

PMID:
29745280
24.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
25.

Annexins in Glaucoma.

Yap TE, Davis BM, Guo L, Normando EM, Cordeiro MF.

Int J Mol Sci. 2018 Apr 17;19(4). pii: E1218. doi: 10.3390/ijms19041218. Review.

26.

Fertility preservation in testicular cancer - predictors of spermatogenesis.

Moody JA, Ahmed K, Horsfield C, Pedersen MRV, Yap T, Shabbir M.

BJU Int. 2018 Aug;122(2):236-242. doi: 10.1111/bju.14214. Epub 2018 Apr 17.

PMID:
29667332
27.

Introduced bullfrog facilitates pathogen invasion in the western United States.

Yap TA, Koo MS, Ambrose RF, Vredenburg VT.

PLoS One. 2018 Apr 16;13(4):e0188384. doi: 10.1371/journal.pone.0188384. eCollection 2018.

28.

A study into the association between local recurrence rates and surgical resection margins in organ-sparing surgery for penile squamous cell cancer.

Sri D, Sujenthiran A, Lam W, Minter J, Tinwell BE, Corbishley CM, Yap T, Sharma DM, Ayres BE, Watkin NW.

BJU Int. 2018 Oct;122(4):576-582. doi: 10.1111/bju.14222. Epub 2018 Apr 27.

PMID:
29604228
29.

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.

Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB.

Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019.

PMID:
29533782
30.

Targeting the PI3K pathway in cancer: are we making headway?

Janku F, Yap TA, Meric-Bernstam F.

Nat Rev Clin Oncol. 2018 May;15(5):273-291. doi: 10.1038/nrclinonc.2018.28. Epub 2018 Mar 6. Review.

PMID:
29508857
31.

TEAM-UP for quality: a cluster randomized controlled trial protocol focused on preventing pressure ulcers through repositioning frequency and precipitating factors.

Yap TL, Kennerly SM, Horn SD, Bergstrom N, Datta S, Colon-Emeric C.

BMC Geriatr. 2018 Feb 20;18(1):54. doi: 10.1186/s12877-018-0744-0.

32.

Precision Oncology Decision Support: Current Approaches and Strategies for the Future.

Kurnit KC, Dumbrava EEI, Litzenburger B, Khotskaya YB, Johnson AM, Yap TA, Rodon J, Zeng J, Shufean MA, Bailey AM, Sánchez NS, Holla V, Mendelsohn J, Shaw KM, Bernstam EV, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2018 Jun 15;24(12):2719-2731. doi: 10.1158/1078-0432.CCR-17-2494. Epub 2018 Feb 2. Review.

PMID:
29420224
33.

Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-edged Sword.

Tang C, Jiang W, Yap TA.

JAMA Oncol. 2018 Aug 1;4(8):1116-1117. doi: 10.1001/jamaoncol.2017.4606. No abstract available.

PMID:
29327039
34.

A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review.

Faure Walker NA, Norris JM, Shah TT, Yap T, Cathcart P, Moore CM, Ahmed HU, Emberton M, Minhas S.

Urol Oncol. 2018 Feb;36(2):67-76. doi: 10.1016/j.urolonc.2017.12.002. Epub 2017 Dec 23. Review.

35.

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.

Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.

Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.

36.

Precision oncology: East meets West.

Subbiah V, Rodon J, Yap TA.

Int J Cancer. 2018 May 1;142(9):1734-1737. doi: 10.1002/ijc.31218. Epub 2018 Jan 4. No abstract available.

PMID:
29243227
37.

Precision Medicine: Progress, Pitfalls, and Promises.

Pilié PG, LoRusso PM, Yap TA.

Mol Cancer Ther. 2017 Dec;16(12):2641-2644. doi: 10.1158/1535-7163.MCT-17-0904. No abstract available.

38.

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.

Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, Yap TA, Plummer R.

J Clin Pharmacol. 2018 Apr;58(4):474-484. doi: 10.1002/jcph.1035. Epub 2017 Nov 26.

PMID:
29178442
39.

Resident Vignettes for Assessing Care Quality in Nursing Homes.

Colón-Emeric CS, Corazzini KN, McConnell ES, Pan W, Toles MP, Hall R, Batchelor-Murphy M, Yap TL, Anderson AL, Burd A, Amarasekara S, Anderson RA.

J Am Med Dir Assoc. 2018 May;19(5):405-410. doi: 10.1016/j.jamda.2017.10.018. Epub 2017 Nov 22.

PMID:
29174560
40.

Batrachochytrium salamandrivorans and the Risk of a Second Amphibian Pandemic.

Yap TA, Nguyen NT, Serr M, Shepack A, Vredenburg VT.

Ecohealth. 2017 Dec;14(4):851-864. doi: 10.1007/s10393-017-1278-1. Epub 2017 Nov 16. Review.

PMID:
29147975
41.

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.

Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.

42.

Myocardial Injury Is Distinguished from Stable Angina by a Set of Candidate Plasma Biomarkers Identified Using iTRAQ/MRM-Based Approach.

Cheow ESH, Cheng WC, Yap T, Dutta B, Lee CN, Kleijn DPV, Sorokin V, Sze SK.

J Proteome Res. 2018 Jan 5;17(1):499-515. doi: 10.1021/acs.jproteome.7b00651. Epub 2017 Nov 7.

PMID:
29068691
43.

Development of Molecularly Driven Targeted Combination Strategies.

Yap TA, Rodon J.

Oncologist. 2017 Dec;22(12):1421-1423. doi: 10.1634/theoncologist.2017-0402. Epub 2017 Oct 16. No abstract available.

44.

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

Minchom A, Thavasu P, Ahmad Z, Stewart A, Georgiou A, O'Brien MER, Popat S, Bhosle J, Yap TA, de Bono J, Banerji U.

PLoS One. 2017 Oct 5;12(10):e0186106. doi: 10.1371/journal.pone.0186106. eCollection 2017.

45.

Effect of Promoting High-Quality Staff Interactions on Fall Prevention in Nursing Homes: A Cluster-Randomized Trial.

Colón-Emeric CS, Corazzini K, McConnell ES, Pan W, Toles M, Hall R, Cary MP Jr, Batchelor-Murphy M, Yap T, Anderson AL, Burd A, Amarasekara S, Anderson RA.

JAMA Intern Med. 2017 Nov 1;177(11):1634-1641. doi: 10.1001/jamainternmed.2017.5073.

46.

Neuronal defects an etiological factor in congenital pelviureteric junction obstruction?

How GY, Chang KTE, Jacobsen AS, Yap TL, Ong CCP, Low Y, Allen JC, Kuick CH, Lim MZL, Laksmi NK.

J Pediatr Urol. 2018 Feb;14(1):51.e1-51.e7. doi: 10.1016/j.jpurol.2017.07.014. Epub 2017 Sep 1.

PMID:
28927720
47.

Anorectal malformation & Hirschsprung's disease: A cross-sectional comparison of quality of life and bowel function to healthy controls.

Nah SA, Ong CCP, Saffari SE, Ong LY, Yap TL, Low Y, Jacobsen AS.

J Pediatr Surg. 2018 Aug;53(8):1550-1554. doi: 10.1016/j.jpedsurg.2017.08.018. Epub 2017 Aug 25.

PMID:
28916047
48.

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Capelan M, Roda D, Geuna E, Rihawi K, Bodla S, Kaye SB, Bhosle J, Banerji U, O'Brien M, de Bono JS, Popat S, Yap TA.

Lung Cancer. 2017 Sep;111:6-11. doi: 10.1016/j.lungcan.2017.06.005. Epub 2017 Jun 15.

49.

Novel insights into mesothelioma biology and implications for therapy.

Yap TA, Aerts JG, Popat S, Fennell DA.

Nat Rev Cancer. 2017 Jul 25;17(8):475-488. doi: 10.1038/nrc.2017.42. Review.

PMID:
28740119
50.

Challenges of Treating Childhood Medulloblastoma in a Country With Limited Resources: 20 Years of Experience at a Single Tertiary Center in Malaysia.

Rajagopal R, Abd-Ghafar S, Ganesan D, Bustam Mainudin AZ, Wong KT, Ramli N, Jawin V, Lum SH, Yap TY, Bouffet E, Qaddoumi I, Krishnan S, Ariffin H, Abdullah WA.

J Glob Oncol. 2016 Jun 15;3(2):143-156. doi: 10.1200/JGO.2015.002659. eCollection 2017 Apr.

Supplemental Content

Support Center